MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-20-2026
Abbott Laboratories Cost of Revenue 2011-2026 | ABT
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Abbott Laboratories
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 19.3 B | 18.7 B | 18 B | 19.1 B | 18.5 B | 15 B | 13.2 B | 12.7 B | 12.4 B | 9.09 B | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 19.3 B | 9.09 B | 15.6 B |
Quarterly Cost of Revenue Abbott Laboratories
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.85 B | 4.47 B | 4.7 B | 4.6 B | 4.46 B | 4.6 B | 4.48 B | 4.33 B | - | 4.63 B | 4.93 B | 4.99 B | - | 4.42 B | 4.95 B | 4.4 B | - | 3.97 B | 3.26 B | 3.28 B | - | 3.36 B | 3.28 B | 3.16 B | - | 3.17 B | 3.28 B | 3.07 B | - | 2.88 B | 3.19 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 4.99 B | 2.88 B | 4.03 B |
Cost of Revenue of other stocks in the Medical devices industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Acutus Medical
AFIB
|
10.3 M | - | -26.83 % | $ 2.62 M |  USA |
 |
Allied Healthcare Products
AHPI
|
24.5 M | - | 3.58 % | $ 2.21 M | USA |
 |
Alphatec Holdings
ATEC
|
232 M | $ 14.07 | 0.21 % | $ 2.11 B | USA |
 |
Cognyte Software Ltd.
CGNT
|
104 M | $ 6.86 | 3.63 % | $ 493 M |  Israel |
 |
ClearPoint Neuro
CLPT
|
12.3 M | $ 13.12 | -13.44 % | $ 355 M | USA |
 |
Apollo Endosurgery
APEN
|
34.4 M | - | - | $ 475 M | USA |
 |
Avinger
AVGR
|
5.65 M | - | -20.74 % | $ 369 K | USA |
 |
AxoGen
AXGN
|
57.9 M | $ 31.16 | -0.21 % | $ 1.43 B | USA |
 |
EDAP TMS S.A.
EDAP
|
37.6 M | $ 4.49 | -2.18 % | $ 167 M |  France |
 |
Axonics Modulation Technologies
AXNX
|
76 M | - | - | $ 3.31 B | USA |
 |
Aziyo Biologics
AZYO
|
13.7 M | - | 1.37 % | $ 20.5 M | USA |
 |
Apyx Medical Corporation
APYX
|
18.6 M | $ 3.4 | -0.58 % | $ 118 M | USA |
 |
Conformis
CFMS
|
38.8 M | - | - | $ 16.4 M | USA |
 |
Electromed
ELMD
|
14 M | $ 24.27 | 2.1 % | $ 205 M | USA |
 |
Bio-Rad Laboratories
BIO
|
1.19 B | $ 269.99 | 0.13 % | $ 7.62 B | USA |
 |
BIOLASE
BIOL
|
32.4 M | - | -13.19 % | $ 166 K | USA |
 |
Bruker Corporation
BRKR
|
1.72 B | $ 40.1 | 0.53 % | $ 5.98 K | USA |
 |
BioSig Technologies
BSGM
|
57 K | - | 37.08 % | $ 85.7 M | USA |
 |
Boston Scientific Corporation
BSX
|
6.22 B | $ 74.86 | 1.87 % | $ 111 B | USA |
 |
InMode Ltd.
INMD
|
79.5 M | $ 14.01 | 0.32 % | $ 906 M | Israel |
 |
IRadimed Corporation
IRMD
|
16.9 M | $ 101.93 | 1.42 % | $ 1.29 B | USA |
 |
CONMED Corporation
CNMD
|
624 M | $ 46.53 | 1.2 % | $ 1.44 B | USA |
 |
Cardiovascular Systems
CSII
|
63.4 M | - | 0.15 % | $ 844 M | USA |
 |
Neovasc
NVCN
|
556 K | - | - | $ 111 M |  Canada |
 |
LivaNova PLC
LIVN
|
448 M | $ 70.52 | 0.33 % | $ 3.85 B |  Britain |
 |
Cutera
CUTR
|
171 M | - | -10.19 % | $ 1.99 M | USA |
 |
Medtronic PLC
MDT
|
11.6 B | $ 96.9 | 0.25 % | $ 125 B | USA |
 |
MiMedx Group
MDXG
|
73 M | $ 5.07 | -4.06 % | $ 749 M | USA |
 |
Delcath Systems
DCTH
|
6.19 M | $ 9.12 | -10.68 % | $ 260 M | USA |
 |
Dynatronics Corporation
DYNT
|
21.4 M | - | 14.99 % | $ 929 K | USA |
 |
Eargo
EAR
|
23 M | - | - | $ 10.2 M | USA |
 |
Nano-X Imaging Ltd.
NNOX
|
21.9 M | $ 2.44 | -0.41 % | $ 143 M | Israel |
 |
Second Sight Medical Products
EYES
|
11.8 M | - | -0.97 % | $ 54.4 M | USA |
 |
Establishment Labs Holdings
ESTA
|
56.5 M | $ 75.24 | -3.9 % | $ 2.12 B |  Costa-rica |
 |
Insulet Corporation
PODD
|
768 M | $ 251.19 | 1.24 % | $ 17.7 B | USA |
 |
GBS
GBS
|
1.81 M | - | -0.57 % | $ 7.12 M | USA |
 |
Quanterix Corporation
QTRX
|
51.7 M | $ 6.11 | -2.86 % | $ 230 M | USA |
 |
Sintx Technologies
SINT
|
784 K | $ 2.9 | -1.36 % | $ 10.8 M | USA |
 |
Globus Medical
GMED
|
958 M | $ 95.66 | -0.58 % | $ 12.9 B | USA |